ISRCTN14031168 https://doi.org/10.1186/ISRCTN14031168

HYpertension in the Very Elderly Trial

Submission date 18/11/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [X] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 18/11/2001	**Overall study status** Completed	
Last Edited 14/11/2013	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof CJ Bulpitt

Contact details
Care of the Elderly
Division of Medicine
ICSM at Hammersmith Hospital
Du Cane Road
London
United Kingdom
W12 0NN
+44 (0)20 8383 3959
c.bulpitt@ic.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00122811

Protocol serial number
RG/97010

Study information

Scientific Title

Acronym
HYVET

Study objectives
To assess the benefits of treating very elderly patients with hypertension.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved by the relevent central and local ethics committees

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Hypertension

Interventions
Two treatment groups:
1. Placebo
2. Indapamide Sustained Release (SR) 1.5 mg plus perindopril 2 - 4 mg if required.

Goal: diastolic blood pressure less than 80 mmHg with systolic pressure less than 150 mmHg.

The patients are followed-up both according to clinical need and every 3 months in the first year and every 6 months thereafter.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Indapamide Sustained Release (SR), perindopril

Primary outcome(s)
Stroke events (fatal and non-fatal).

Key secondary outcome(s))

1. Total mortality
2. Cardiovascular mortality
3. Cardiac mortality
4. Stroke mortality
5. Skeletal fracture

Completion date
31/12/2009

Eligibility

Key inclusion criteria
1. People 80 years old and above
2. Sustained systolic pressure 160 - 199 mmHg and diastolic (phase V) pressure 90 - 109 mmHg
3. No evidence of renal failure or co-morbidity requiring anti-hypertensive treatment

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Senior

Sex
All

Key exclusion criteria
Does not comply with above inclusion criteria.

Date of first enrolment
01/01/2001

Date of final enrolment
31/12/2009

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Care of the Elderly
London

United Kingdom
W12 0NN

Sponsor information

Organisation
British Heart Foundation (UK)

ROR
https://ror.org/02wdwnk04

Funder(s)

Funder type
Charity

Funder Name
British Heart Foundation (UK) (ref: RG/97010)

Alternative Name(s)
the_bhf, The British Heart Foundation, BHF

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
United Kingdom

Funder Name
Institut de Recherches Internationales Servier (France)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2008		Yes	No
Results article	results	01/07/2010		Yes	No
Protocol article	main trial protocol	01/07/2001		Yes	No
Protocol article	sub-study protocol	19/12/2006		Yes	No